Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CTTQ Acquires Global Rights to Clinical Stage Symphogen Immunotherapy

publication date: May 23, 2022

Chia Tai‑Tianqing Pharma (CTTQ), a Nanjing subsidiary of Sino Biopharma, will acquire global rights to an anti-LAG3 mAb from Symphogen A/S of Denmark. Sym022 is a mAb that binds LAG3 to block the interaction with MHCII, which increases T cell proliferation and production of cytokines. In two Phase I trials, Sym022 proved itself to be safe and well-tolerated as a monotherapy and in combination with checkpoint inhibitors. Financial details of the transaction were not disclosed. Symphogen is the Antibody Center of Excellence for Servier, a privately held French biopharma. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here